Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up study of ATX-101 for reduction of submental fat
2011-005026-21Phase 3Completed
- Sponsor
- Kythera Biopharmaceuticals
- Start
- Nov 2011
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ATX101 in Submental lipomatosis and Lipohypertrophy (LH), sponsored by Kythera Biopharmaceuticals. Primary endpoint: Long-term efficacy and safety of ATX-101 in the submental area. Started Nov 2011; status: completed.
02
Drugs
ATX101
03
Conditions
Submental lipomatosisLipohypertrophy (LH)
Beyond the preview
Go deeper on 2011-005026-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005026-21.